| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2035800 | Cell | 2011 | 12 Pages |
SummaryMetabolites in the kynurenine pathway, generated by tryptophan degradation, are thought to play an important role in neurodegenerative disorders, including Alzheimer's and Huntington's diseases. In these disorders, glutamate receptor-mediated excitotoxicity and free radical formation have been correlated with decreased levels of the neuroprotective metabolite kynurenic acid. Here, we describe the synthesis and characterization of JM6, a small-molecule prodrug inhibitor of kynurenine 3-monooxygenase (KMO). Chronic oral administration of JM6 inhibits KMO in the blood, increasing kynurenic acid levels and reducing extracellular glutamate in the brain. In a transgenic mouse model of Alzheimer's disease, JM6 prevents spatial memory deficits, anxiety-related behavior, and synaptic loss. JM6 also extends life span, prevents synaptic loss, and decreases microglial activation in a mouse model of Huntington's disease. These findings support a critical link between tryptophan metabolism in the blood and neurodegeneration, and they provide a foundation for treatment of neurodegenerative diseases.
Graphical AbstractFigure optionsDownload full-size imageDownload high-quality image (80 K)Download as PowerPoint slideHighlights► JM6 is a novel prodrug that inhibits kynurenine 3-monooxygenase (KMO) ► Oral delivery of JM6 ameliorates neurodegenerative symptoms in mice ► Inhibition of KMO in the blood sends a neuroprotective signal to the brain
